Abstract
Serpins are key players in the regulation of various physiological functions. In addition, their functional loss owing to genetic variations and polymerization causes severe diseases. It is therefore of interest to target serpins for therapeutic interventions. Increasing knowledge of structure, mechanisms of function and dysfunction, as well as natural modulation of human serpins has opened up new possibilities for structure-guided design of modulators. These might provide the possibility of both inhibition and mimicking of serpin function regarding protease inhibition. Also interference with pathological serpin polymerization might be achievable. Peptides are promising molecules for this purpose since they have been shown to be potent and selective inhibitors of protein–protein interactions. This chapter illustrates how serpin action can be modulated by peptides and how these might be useful for therapeutic intervention.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anderson ED, Thomas L, Hayflick JS, Thomas G (1993) Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed α1-antitrypsin variant. J Biol Chem 268(33):24887–24891
Aulak KS, Eldering E, Hack CE, Lubbers YP, Harrison RA, Mast A, Cicardi M, Davis AE (1993) A hinge region mutation in C1-inhibitor (Ala436 → Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J Biol Chem 268(24):18088–18094
Baglin TP, Carrell RW, Church FC, Esmon CT, Huntington JA (2002) Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc Natl Acad Sci USA 99(17):11079–11084. doi:10.1073/pnas.162232399
Basak A, Lotfipour F (2005) Modulating furin activity with designed mini-PDX peptides: synthesis and in vitro kinetic evaluation. FEBS Lett 579(21):4813–4821. doi:10.1016/j.febslet.2005.07.062
Björk I, Ylinenjärvi K, Olson ST, Bock PE (1992) Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the P1 to P14 region of the putative reactive bond loop of the inhibitor. J Biol Chem 267(3):1976–1982
Bodenstine TM, Seftor REB, Khalkhali-Ellis Z, Seftor EA, Pemberton PA, Hendrix MJC (2012) Maspin: molecular mechanisms and therapeutic implications. Cancer Metastasis Rev 31(3-4):529–551. doi:10.1007/s10555-012-9361-0
Bruce D, Perry DJ, Borg J-Y, Carrell RW, Wardell MR (1994) Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn → Asp). J Clin Invest 94(6):2265–2274. doi:10.1172/JCI117589
Carrell R, Travis J (1985) α1-Antitrypsin and the serpins: variation and countervariation. Trends Biochem Sci 10(1):20–24. doi:10.1016/0968-0004(85)90011-8
Carrell RW, Evans DL, Stein PE (1991) Mobile reactive centre of serpins and the control of thrombosis. Nature 353(6344):576–578. doi:10.1038/353576a0
Chang W-SW (1998) Latent α1-antichymotrypsin: a molecular explanation for the inactivation of α1-antichymotrypsin in chronic bronchitis and emphysema. J Biol Chem 273(6):3695–3701. doi:10.1074/jbc.273.6.3695
Chang WS, Wardell MR, Lomas DA, Carrell RW (1996) Probing serpin reactive-loop conformations by proteolytic cleavage. Biochem J 314(Pt 2):647–653
Chang W-SW, Whisstock J, Hopkins PC, Lesk AM, Carrell RW, Wardell MR (1997) Importance of the release of strand 1C to the polymerization mechanism of inhibitory serpins. Protein Sci 6(1):89–98. doi:10.1002/pro.5560060110
Chang Y-P, Mahadeva R, Chang W-SW, Shukla A, Dafforn TR, Chu Y-H (2006) Identification of a 4-mer peptide inhibitor that effectively blocks the polymerization of pathogenic Z α1-antitrypsin. Am J Respir Cell Mol Biol 35(5):540–548. doi:10.1165/rcmb.2005-0207OC
Chang Y-P, Mahadeva R, Chang W-SW, Lin S-C, Chu Y-H (2009) Small-molecule peptides inhibit Z α1-antitrypsin polymerization. J Cell Mol Med 13(8b):2304–2316. doi:10.1111/j.1582-4934.2008.00608.x
Chavakis T (2002) A novel antithrombotic role for high molecular weight kininogen as inhibitor of plasminogen activator inhibitor-1 function. J Biol Chem 277(36):32677–32682. doi:10.1074/jbc.M204010200
Chavakis T, Kanse SM, Lupu F, Hammes H-P, Müller-Esterl W, Pixley RA, Colman RW, Preissner KT (2000) Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor–dependent interactions. Blood 96(2):514–522
Chowdhury P, Wang W, Lavender S, Bunagan MR, Klemke JW, Tang J, Saven JG, Cooperman BS, Gai F (2007) Fluorescence correlation spectroscopic study of serpin depolymerization by computationally designed peptides. J Mol Biol 369(2):462–473. doi:10.1016/j.jmb.2007.03.042
Congote LF (2006) The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1. Biochem Biophys Res Commun 343(2):617–622. doi:10.1016/j.bbrc.2006.02.190
Congote LF, Temmel N (2004) The C-terminal 26-residue peptide of serpin A1 stimulates proliferation of breast and liver cancer cells: role of protein kinase C and CD47. FEBS Lett 576(3):343–347. doi:10.1016/j.febslet.2004.09.035
Congote LF, Temmel N, Sadvakassova G, Dobocan MC (2008) Comparison of the effects of serpin A1, a recombinant serpin A1-IGF chimera and serpin A1 C-terminal peptide on wound healing. Peptides 29(1):39–46. doi:10.1016/j.peptides.2007.10.011
D’Amico S, Martial JA, Struman I (2012) A peptide mimicking the C-terminal part of the reactive center loop induces the transition to the latent form of plasminogen activator inhibitor type-1. FEBS Lett 586(6):686–692. doi:10.1016/j.febslet.2012.02.013
Davis RL, Shrimpton AE, Holohan PD, Bradshaw C, Feiglin D, Collins GH, Sonderegger P, Kinter J, Becker LM, Lacbawan F, Krasnewich D, Muenke M, Lawrence DA, Yerby MS, Shaw CM, Gooptu B, Elliott PR, Finch JT, Carrell RW, Lomas DA (1999) Familial dementia caused by polymerization of mutant neuroserpin. Nature 401(6751):376–379. doi:10.1038/43894
Dementiev A, Simonovic M, Volz K, Gettins PGW (2003) Canonical inhibitor-like interactions explain reactivity of α1-Proteinase inhibitor Pittsburgh and antithrombin with proteinases. J Biol Chem 278(39):37881–37887. doi:10.1074/jbc.M305195200
Dementiev A, Petitou M, Herbert J-M, Gettins PGW (2004) The ternary complex of antithrombin-anhydrothrombin-heparin reveals the basis of inhibitor specificity. Nat Struct Mol Biol 11(9):863–867. doi:10.1038/nsmb810
Dementiev A, Dobo J, Gettins PGW (2006) Active site distortion is sufficient for proteinase inhibition by serpins: structure of the covalent complex of α1-proteinase inhibitor with porcine pancreatic elastase. J Biol Chem 281(6):3452–3457. doi:10.1074/jbc.M510564200
Dufour EK, Denault J-B, Hopkins PC, Leduc R (1998) Serpin-like properties of α1-antitrypsin Portland towards furin convertase. FEBS Lett 426(1):41–46. doi:10.1016/S0014-5793(98)00307-X
Egelund R, Rodenburg KW, Andreasen PA, Rasmussen MS, Guldberg RE, Petersen TE (1998) An ester bond linking a fragment of a serine proteinase to its serpin inhibitor. Biochemistry 37(18):6375–6379. doi:10.1021/bi973043+
Eitzman DT, Fay WP, Lawrence DA, Francis-Chmura AM, Shore JD, Olson ST, Ginsburg D (1995) Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 95(5):2416–2420. doi:10.1172/JCI117937
Ekeowa UI, Freeke J, Miranda E, Gooptu B, Bush MF, Perez J, Teckman J, Robinson CV, Lomas DA (2010) Defining the mechanism of polymerization in the serpinopathies. Proc Natl Acad Sci USA 107(10):17146–17151. doi:10.1073/pnas.1004785107
Eldering E, Verpy E, Roem D, Meo T, Tosi M (1995) COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization. J Biol Chem 270(6):2579–2587. doi:10.1074/jbc.270.6.2579
Elliott PR, Pei XY, Dafforn TR, Lomas DA (2000) Topography of a 2.0 Å structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci 9(7):1274–1281. doi:10.1110/ps.9.7.1274
Filleur S, Nelius T, de Riese W, Kennedy RC (2009) Characterization of PEDF: a multi-functional serpin family protein. J Cell Biochem 106(5):769–775. doi:10.1002/jcb.22072
Fitton HL, Pike RN, Carrell RW, Chang WS (1997) Mechanisms of antithrombin polymerisation and heparin activation probed by the insertion of synthetic reactive loop peptides. Biol Chem 378(9):1059–1063. doi:10.1515/bchm.1997.378.9.1059
Gettins PGW, Olson ST (2009) Exosite determinants of serpin specificity. J Biol Chem 284(31):20441–20445. doi:10.1074/jbc.R800064200
Gooptu B, Hazes B, Chang W-SW, Dafforn TR, Carrell RW, Read RJ, Lomas DA (2000) Inactive conformation of the serpin α1-antichymotrypsin indicates two-stage insertion of the reactive loop: Implications for inhibitory function and conformational disease. Proc Natl Acad Sci USA 97(1):67–72. doi:10.1073/pnas.97.1.67
Gooptu B, Dickens JA, Lomas DA (2014) The molecular and cellular pathology of α1-antitrypsin deficiency. Trends Mol Med 20(2):116–127. doi:10.1016/j.molmed.2013.10.007
Hedstrom L (2002) Serine protease mechanism and specificity. Chem Rev 102(12):4501–4524. doi:10.1021/cr000033x
Heiker JT, Klöting N, Kovacs P, Kuettner EB, Sträter N, Schultz S, Kern M, Stumvoll M, Blüher M, Beck-Sickinger AG (2013) Vaspin inhibits kallikrein 7 by serpin mechanism. Cell Mol Life Sci 70(14):2569–2583. doi:10.1007/s00018-013-1258-8
Heit C, Jackson BC, McAndrews M, Wright MW, Thompson DC, Silverman GA, Nebert DW, Vasiliou V (2013) Update of the human and mouse SERPIN gene superfamily. Hum Genomics 7(1):22. doi:10.1186/1479-7364-7-22
Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto L, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS (2005) Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 102(30):10610–10615. doi:10.1073/pnas.0504703102
Huang X, Dementiev A, Olson ST, Gettins PGW (2010) Basis for the specificity and activation of the serpin protein Z-dependent proteinase inhibitor (ZPI) as an inhibitor of membrane-associated factor Xa. J Biol Chem 285(26):20399–20409. doi:10.1074/jbc.M110.112748
Huang X, Rezaie AR, Broze GJ, Olson ST (2011) Heparin is a major activator of the anticoagulant serpin, protein Z-dependent protease inhibitor. J Biol Chem 286(11):8740–8751. doi:10.1074/jbc.M110.188375
Huntington JA (2000) The conformational activation of antithrombin: a 2.85-Å structure of a fluorescein derivative reveals an electrostatic link between the hinge and heparin binding regions. J Biol Chem 275(20):15377–15383. doi:10.1074/jbc.275.20.15377
Huntington JA, Whisstock JC (2010) Molecular contortionism – on the physical limits of serpin ‘loop-sheet’ polymers. Biol Chem 391(8):973–982. doi:10.1515/bc.2010.085
Huntington JA, Read RJ, Carrell RW (2000) Structure of a serpin-protease complex shows inhibition by deformation. Nature 407(6806):923–926. doi:10.1038/35038119
Izuhara K, Ohta S, Kanaji S, Shiraishi H, Arima K (2008) Recent progress in understanding the diversity of the human ov-serpin/clade B serpin family. Cell Mol Life Sci 65(16):2541–2553. doi:10.1007/s00018-008-8049-7
Jankova L (2001) Crystal structure of the complex of plasminogen activator inhibitor 2 with a peptide mimicking the reactive center loop. J Biol Chem 276(46):43374–43382. doi:10.1074/jbc.M103021200
Jean F, Stella K, Thomas L, Liu G, Xiang Y, Reason AJ, Thomas G (1998) α1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci USA 95(13):7293–7298. doi:10.1073/pnas.95.13.7293
Jia Q, Jiang X, Yu F, Qiu J, Kang X, Cai L, Li L, Shi W, Liu S, Jiang S, Liu K (2012) Short cyclic peptides derived from the C-terminal sequence of α1-antitrypsin exhibit significant anti-HIV-1 activity. Bioorg Med Chem Lett 22(7):2393–2395. doi:10.1016/j.bmcl.2012.02.037
Kaslik G, Kardos J, Szabó E, Szilágyi L, Závodszky P, Westler WM, Markley JL, Gráf L (1997) Effects of serpin binding on the target proteinase: global stabilization, localized increased structural flexibility, and conserved hydrogen bonding at the active site. Biochemistry 36(18):5455–5464. doi:10.1021/bi962931m
Law RH, Zhang Q, McGowan S, Buckle AM, Silverman GA, Wong W, Rosado CJ, Langendorf CG, Pike RN, Bird PI et al (2006) An overview of the serpin superfamily. Genome Biol 7(5):216. doi:10.1186/gb-2006-7-5-216
Lawrence DA (1995) The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into β-sheet A. J Biol Chem 270(46):27942–27947. doi:10.1074/jbc.270.46.27942
Lawrence DA, Ginsburg D, Day DE, Berkenpas MB, Verhamme IM, Kvassman J-O, Shore JD (1995) Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 270(43):25309–25312. doi:10.1074/jbc.270.43.25309
Li W, Huntington JA (2008) The heparin binding site of protein C inhibitor is protease-dependent. J Biol Chem 283(51):36039–36045. doi:10.1074/jbc.M805974200
Li W, Johnson DJD, Esmon CT, Huntington JA (2004) Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol 11(9):857–862. doi:10.1038/nsmb811
Lin H-Y, Muller YA, Hammond GL (2010) Molecular and structural basis of steroid hormone binding and release from corticosteroid-binding globulin. Mol Cell Endocrinol 316(1):3–12. doi:10.1016/j.mce.2009.06.015
Lin Z, Jiang L, Yuan C, Jensen JK, Zhang X, Luo Z, Furie BC, Furie B, Andreasen PA, Huang M (2011) Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J Biol Chem 286(9):7027–7032. doi:10.1074/jbc.M110.204537
Liu B, Schofield CJ, Wilmouth RC (2006) Structural analyses on intermediates in serine protease catalysis. J Biol Chem 281(33):24024–24035. doi:10.1074/jbc.M600495200
Loebermann H, Tokuoka R, Deisenhofer J, Huber R (1984) Human α1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol 177(3):531–557. doi:10.1016/0022-2836(84)90298-5
Lomas DA, Evans DL, Finch JT, Carrell RW (1992) The mechanism of Z α1-antitrypsin accumulation in the liver. Nature 357(6379):605–607. doi:10.1038/357605a0
Lomas DA, Evans DL, Stone SR, Chang WSW, Carrell RW (1993) Effect of the Z mutation on the physical and inhibitory properties of α1-antitrypsin. Biochemistry 32(2):500–508. doi:10.1021/bi00053a014
Luckett S, Garcia RS, Barker JJ, Konarev AV, Shewry PR, Clarke AR, Brady RL (1999) High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds. J Mol Biol 290(2):525–533. doi:10.1006/jmbi.1999.2891
Mäde V, Els-Heindl S, Beck-Sickinger AG (2014) Automated solid-phase peptide synthesis to obtain therapeutic peptides. Beilstein J Org Chem 10:1197–1212. doi:10.3762/bjoc.10.118
Mahadeva R (2002) 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization: implications for the prevention of Z α1-antitrypsin-related cirrhosis. J Biol Chem 277(9):6771–6774. doi:10.1074/jbc.C100722200
Mallya M, Phillips RL, Saldanha SA, Gooptu B, Leigh Brown SC, Termine DJ, Shirvani AM, Wu Y, Sifers RN, Abagyan R, Lomas DA (2007) Small molecules block the polymerization of Z α1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem 50(22):5357–5363. doi:10.1021/jm070687z
Mast AE, Enghild JJ, Salvesen G (1992) Conformation of the reactive site loop of α1-proteinase inhibitor probed by limited proteolysis. Biochemistry 31(10):2720–2728. doi:10.1021/bi00125a012
Mirochnik Y, Aurora A, Schulze-Hoepfner FT, Deabes A, Shifrin V, Beckmann R, Polsky C, Volpert OV (2009) Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth. Clin Cancer Res 15(5):1655–1663. doi:10.1158/1078-0432.CCR-08-2113
Morgan L, Broughton Pipkin F, Kalsheker N (1996) Angiotensinogen: molecular biology, biochemistry and physiology. Int J Biochem Cell Biol 28(11):1211–1222. doi:10.1016/S1357-2725(96)00086-6
Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ (1992) Structural basis of latency in plasminogen activator inhibitor-1. Nature 355(6357):270–273. doi:10.1038/355270a0
Mushunje A, Evans G, Brennan SO, Carrell RW, Zhou A (2004) Latent antithrombin and its detection, formation and turnover in the circulation. J Thromb Haemost 2(12):2170–2177. doi:10.1111/j.1538-7836.2004.01047.x
Ngamkitidechakul C, Warejcka DJ, Burke JM, O’Brien WJ, Twining SS (2003) Sufficiency of the reactive site loop of maspin for induction of cell-matrix adhesion and inhibition of cell invasion: conversion of ovalbumin to a maspin-like molecule. J Biol Chem 278(34):31796–31806. doi:10.1074/jbc.M302408200
Parfrey H, Mahadeva R, Ravenhill NA, Zhou A, Dafforn TR, Foreman RC, Lomas DA (2003) Targeting a surface cavity of α1-antitrypsin to prevent conformational disease. J Biol Chem 278(35):33060–33066. doi:10.1074/jbc.M302646200
Patschull AOM, Segu L, Nyon MP, Lomas DA, Nobeli I, Barrett TE, Gooptu B (2011) Therapeutic target-site variability in α1-antitrypsin characterized at high resolution. Acta Crystallogr Sect F: Struct Biol Cryst Commun 67(12):1492–1497. doi:10.1107/S1744309111040267
Picard V (2003) Antithrombin Phe229Leu: a new homozygous variant leading to spontaneous antithrombin polymerization in vivo associated with severe childhood thrombosis. Blood 102(3):919–925. doi:10.1182/blood-2002-11-3391
Qureshi SH, Lu Q, Manithody C, Yang L, Rezaie AR (2014) Characterization of the protein Z-dependent protease inhibitor interactive-sites of protein Z. BBA-Proteins Proteom 1844(9):1631–1637. doi:10.1016/j.bbapap.2014.06.011
Rau JC, Beaulieu LM, Huntington JA, Church FC (2007) Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 5(Suppl 1):102–115. doi:10.1111/j.1538-7836.2007.02516.x
Ravenhill L, Wagstaff L, Edwards DR, Ellis V, Bass R (2010) G-helix of maspin mediates effects on cell migration and adhesion. J Biol Chem 285(47):36285–36292. doi:10.1074/jbc.M110.177253
Ricagno S, Pezzullo M, Barbiroli A, Manno M, Levantino M, Santangelo MG, Bonomi F, Bolognesi M (2010) Two latent and two hyperstable polymeric forms of human neuroserpin. Biophys J 99(10):3402–3411. doi:10.1016/j.bpj.2010.09.021
Santangelo MG, Noto R, Levantino M, Cupane A, Ricagno S, Pezzullo M, Bolognesi M, Mangione MR, Martorana V, Manno M (2012) On the molecular structure of human neuroserpin polymers. Proteins 80(1):8–13. doi:10.1002/prot.23197
Sauk JJ, Nikitakis N, Siavash H et al (2005) Hsp47 a novel collagen binding serpin chaperone, autoantigen and therapeutic target. Front Biosci 10(2):107–118. doi:10.2741/1513
Schechter I, Berger A (1967) On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27(2):157–162. doi:10.1016/S0006-291X(67)80055-X
Schulze AJ, Baumann U, Knof S, Jaeger E, Huber R, Laurell C-B (1990) Structural transition of α1-antitrypsin by a peptide sequentially similar to β-strand s4A. Eur J Biochem 194(1):51–56. doi:10.1111/j.1432-1033.1990.tb19425.x
Schulze AJ, Frohnert PW, Engh RA, Huber R (1992) Evidence for the extent of insertion of the active site loop of intact α1 proteinase inhibitor in β-sheet A. Biochemistry 31(33):7560–7565. doi:10.1021/bi00148a017
Schussler GC (2000) The thyroxine-binding proteins. Thyroid 10(2):141–149. doi:10.1089/thy.2000.10.141
Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PGW, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold-O’Donnell E, Salvesen GS, Travis J, Whisstock JC (2001) The serpins are an expanding superfamily of structurally similar but functionally diverse proteins: evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276(36):33293–33296. doi:10.1074/jbc.R100016200
Skinner R, Chang W-SW, Jin L, Pei X, Huntington JA, Abrahams J-P, Carrell RW, Lomas DA (1998) Implications for function and therapy of a 2.9 Å structure of binary-complexed antithrombin. J Mol Biol 283(1):9–14. doi:10.1006/jmbi.1998.2083
Stratikos E, Gettins PG (1999) Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive center loop into β-sheet A. Proc Natl Acad Sci USA 96(9):4808–4813. doi:10.1073/pnas.96.9.4808
Walker B, Lynas JF (2001) Strategies for the inhibition of serine proteases. Cell Mol Life Sci 58(4):596–624. doi:10.1007/PL00000884
Wei Z, Yan Y, Carrell RW, Zhou A (2009) Crystal structure of protein Z-dependent inhibitor complex shows how protein Z functions as a cofactor in the membrane inhibition of factor X. Blood 114(17):3662–3667. doi:10.1182/blood-2009-04-210021
Whisstock JC, Pike RN, Jin L, Skinner R, Pei XY, Carrell RW, Lesk AM (2000) Conformational changes in serpins: II. The mechanism of activation of antithrombin by heparin. J Mol Biol 301(5):1287–1305. doi:10.1006/jmbi.2000.3982
Wright PA, Rostom AA, Robinson CV, Schofield CJ (2000) Mass spectrometry reveals elastase inhibitors from the reactive centre loop of α1-antitrypsin. Bioorg Med Chem Lett 10(11):1219–1221. doi:10.1016/S0960-894X(00)00194-3
Xue Y, Björquist P, Inghardt T, Linschoten M, Musil D, Sjölin L, Deinum J (1998) Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Structure 6(5):627–636. doi:10.1016/S0969-2126(98)00064-1
Yamasaki M, Li W, Johnson DJD, Huntington JA (2008) Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature 455(7217):1255–1258. doi:10.1038/nature07394
Yamasaki M, Sendall TJ, Harris LE, Lewis GMW, Huntington JA (2010) Loop-sheet mechanism of serpin polymerization tested by reactive center loop mutations. J Biol Chem 285(40):30752–30758. doi:10.1074/jbc.M110.156042
Yamasaki M, Sendall TJ, Pearce MC, Whisstock JC, Huntington JA (2011) Molecular basis of α1-antitrypsin deficiency revealed by the structure of a domain-swapped trimer. EMBO Rep 12(10):1011–1017. doi:10.1038/embor.2011.171
Ye S, Cech AL, Belmares R, Bergstrom RC, Tong Y, Corey DR, Kanost MR, Goldsmith EJ (2001) The structure of a Michaelis serpin-protease complex. Nat Struct Mol Biol 8(11):979–983. doi:10.1038/nsb1101-979
Youn B-S, Kloting N, Kratzsch J, Lee N, Park JW, Song E-S, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, Bluher M (2008) Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57(2):372–377. doi:10.2337/db07-1045
Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ (2003) How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10(7):541–544. doi:10.1038/nsb943
Zhou A, Stein PE, Huntington JA, Sivasothy P, Lomas DA, Carrell RW (2004) How small peptides block and reverse serpin polymerisation. J Mol Biol 342(3):931–941. doi:10.1016/j.jmb.2004.07.078
Acknowledgments
We gratefully acknowledge the graduate school “Leipzig School of Natural Sciences—Building with Molecules and Nano-objects” (BuildMoNa) and the “Deutsche Forschungsgemeinschaft” (DFG; SFB1052/C2) for funding.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Jendrny, C., Beck-Sickinger, A.G. (2015). Peptides as Modulators of Serpin Action. In: Geiger, M., Wahlmüller, F., Furtmüller, M. (eds) The Serpin Family. Springer, Cham. https://doi.org/10.1007/978-3-319-22711-5_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-22711-5_3
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-22710-8
Online ISBN: 978-3-319-22711-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)